Table 1.
Parameters | Control | TAA-treated | RSV-treated | TAA+RSV-treated |
---|---|---|---|---|
BUN (mg/mg protein) | 18.31 ± 2.9b | 44.03 ± 1.9acd | 20.7 ± 1.6b | 17.88 ± 2.0b |
Creatinine (mg/mg protein) | 0.31 ± 0.06bcd | 0.58 ± 0.03ac | 0.44 ± 0.02bd | 0.37 ± 0.03bc |
Creatine kinase (U/mg protein) | 57.71 ± 2.6b | 67.66 ± 1.6ac | 58.26 ± 1.8b | 60.28 ± 5.9b |
Lipid peroxidation (mmoles/mg protein) | 2.20 ± 0.537bc | 4.24 ± 0.57acd | 1.81 ± 0.71abd | 2.38 ± 0.12b |
Catalase (U/mg protein) | 1.08 ± 0.46bd | 0.33 ± 0.06ad | 0.98 ± 0.22b | 1.33 ± 0.23b |
aSignificant (P < 0.05) compared to control; bsignificant (P < 0.05) compared to TAA-treated group; csignificant (P < 0.05) compared to with the RSV-treated group; dsignificant (P < 0.05) compared to simultaneous treatment of TAA+RSV-treated group.